Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (763)	11/2/1998 12:41:00 PM
From: Rocketman	Read Replies (1) \| Respond to of 3202

PKN taking care of customers....last. Competing with customers....first. Rman

To: Vector1 who wrote (763)	11/4/1998 11:46:00 AM
From: Rocketman	Respond to of 3202

Incyte Issued First EST Gene Patent Wednesday November 4, 8:31 am Eastern Time Company Press Release SOURCE: Incyte Pharmaceuticals, Inc. PALO ALTO, Calif., Nov. 4 /PRNewswire/ -- Incyte Pharmaceuticals Inc. (Nasdaq: INCY - news) today announced that the United States Patent and Trademark Office (PTO) has issued to Incyte Patent No. 5,817,479 entitled ''Human Kinase Homologs''. This patent, which issued on October 6, 1998, is the first of Incyte's EST patents to issue and covers expressed sequence tags (ESTs) which encode 44 novel protein kinases. The '479 patent describes the discovery and sequencing of a set of polynucleotides or ESTs which belong to the kinase gene family. Kinases play a critical role in the signaling processes involved in cellular responses to drugs and disease. These EST markers will be made commercially available on Incyte's microarray platform for use in research programs by Incyte's genomic partners. Incyte's partners include 22 of the world's largest pharmaceutical companies, which account for more than 60% of the research and development spending by the top 50 pharmaceutical companies. The '479 patent and other Incyte gene product intellectual property are broadly and nonexclusively available to Incyte's pharmaceutical partners for their drug discovery and development programs. ''Since its inception, Incyte has been assembling a broad intellectual property portfolio to support pharmaceutical research and development, including EST and full-length gene patents, methods for fabricating microarrays, sample preparation methods, and proprietary bioinformatics software to manage and analyze genomic data,'' said Roy A. Whitfield, Chief Executive Officer of Incyte. ''This new patent is an important advance toward generating proprietary assay systems, including microarray products for industrial scale life sciences applications in research, diagnostics and therapeutics.'' Incyte has generated a broad intellectual property portfolio that includes 92 issued US patents and US patent applications filed that cover over 1,500 full-length genes and over 1.2 million EST sequences. Prospective uses for these genes includes their use as therapeutic targets, in gene therapy, and as probes for hybridization experiments such as microarrays. Incyte Pharmaceuticals, Inc. is a leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. The Incyte General division develops and markets gene discovery and expression products -- including databases, genomic data management software, microarray-based gene expression services, and related reagents -- enabling the pharmaceutical industry to identify new targets and pathways for drug discovery and development. The Incyte Genetics division will provide databases, bioinformatics, and services relating to sequencing and mapping the human genome and identifying gene sequence variation, enabling the pharmaceutical industry to utilize pharmacogenetics as an integral part of pharmaceutical discovery and development. For more information, visit Incyte's web site at www.incyte.com. Except for the historical information contained herein, the matters set forth in this press release, including statements as to the potential uses of ESTs and other gene sequences are forward-looking statements within the meaning of the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the ability to implement technological improvements; uncertainties related to the issuance and enforcement of patents; the impact of alternative technological advances and competition; and other risks detailed from time to time in Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 1998. Incyte disclaims any intent or obligation to update these forward-looking statements. SOURCE: Incyte Pharmaceuticals, Inc.